Sponsored by the North American Center for Continuing Medical Education (NACCME)
Target Audience
Dermatologists, plastic surgeons and internists who treat patients with psoriasis
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- distinguish recent anti-TNF therapeutic safety and efficacy data specifically relating to the treatment of chronic plaque psoriasis
- evaluate the latest data regarding anti-TNF therapies used in the treatment of psoriasis
- apply the clinical research information to the selection of the treatment regimen most suitable for their patients with psoriasis based upon an understanding of the clinical trial data.
CME Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the North American Center for Continuing Medical Education (NACCME), Educational Awareness Solutions and Research and Outcomes Institute. NACCME is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.
NACCME designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
A score of 70 percent or above will comprise a passing grade. A documentation of credit will be awarded to participants who successfully complete the exam. Those who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.
Release Date: June 1, 2008
Expiration Date: June 30, 2009
Estimated time to complete: 1 hour
There is no fee associated with this activity.
Grant Support
This activity is supported by an educational donation from Amgen and Wyeth Pharmaceuticals
Participating Faculty
Leon H. Kircik, M.D.
James Q. Del Rosso, D.O., FAOCD
Activity Overview
To be eligible for a documentation of credit, participants must read all article content, log on to www.princetoncme.com to complete the posttest with a score of 70% or better, and complete the online evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print a documentation of credit. Please e-mail info@naccme.com or call (609) 371-1137 if you have questions or need additional information.
Financial Disclosure and Conflicts of Interest
Off-Label/Unapproved Usage Disclosure: This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither NACCME, Amgen nor Wyeth recommends the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Disclosures: All those with control over the content of continuing education programs sponsored by NACCME are expected to disclose whether they do or do not have any real or apparent conflicts of interest or other relationships related to the content of their articles. It is not assumed that these relationships will have an adverse impact on the articles; they are simply noted here to fully inform participants.
Planners/Authors: Dr. Kircik has disclosed that he has received funding as an investigator, consultant or speaker from Amgen. Dr. Del Rosso has disclosed that he has received grant/research support from Coria Laboratories, Ltd., Glaxo Dermatology, Medicis Pharmaceutical Corp, and Ortho Neutrogena. He is a consultant to QLT Inc. SkinMedica, Stiefel Laboratories and Ranbaxy Pharmaceuticals. He is a scientific advisor to Unilever,Warner Chilcott, Allergan Inc., Obagi Medical Products, and he is a member of the speakers’ bureau for all of the above named companies.
Reviewers: Dr. Nancy Feiwel and Dr. Robert Kirsner have disclosed that they have no significant financial relationship with any organization that could be perceived as a real or apparent conflict of interest.
Medical Writer: Mr. Michael Jorrin has disclosed that he has no significant financial relationship with any organization that could be perceived as a real or apparent conflict of interest.
Editor: Carol Hampton, Ph.D., has disclosed that she has no significant financial relationship with any organization that could be perceived as a real or apparent conflict of interest.
Planners: P. Levy, NACCME, P. Schwartz, EAS, and N. Grabowski, ROI have disclosed that they have no significant financial relationships with any organization that could be perceived as a real or apparent conflict of interest.
